



PRODUCT LIST 2024

List of Peptide API			
Molecules*	Therapeutic class	Stage	Commercial For
Leuprolide Acetate USP	GnRH agonist and an antineoplastic agent	Commercial	ROW
Octreotide Acetate USP	Treatment of Acromegaly and Carcinoid Tumors	Commercial	ROW
Octreotide Acetate EP	Treatment of Acromegaly and Carcinoid Tumors	Commercial	ROW
Ganirelix Acetate	GnRH antagonist	Commercial	ROW
Triptorelin Pamoate/Acetate	GnRH agonist and an antineoplastic agent	Commercial	ROW
Cetrorelix Acetate	GnRH antagonist and an antineoplastic agent	Commercial	ROW
Degarelix Acetate	GnRH antagonist and an antineoplastic agent	Commercial	ROW
Goserelin acetate	GnRH antagonist and an antineoplastic agent	Commercial	ROW
Goserelin BP	GnRH antagonist and an antineoplastic agent	Commercial	ROW
Micafungin Sodium	Antifungal	Commercial	ROW

Micafungin Sodium USP	Antifungal	Commercial	ROW
Anidulafungin	Antifungal	Commercial	ROW
Desmopressin EP	Anti-diuretic Hormone	Commercial	ROW
Desmopressin IP	Anti-diuretic Hormone	Commercial	ROW
Desmopressin Acetate USP	Anti-diuretic Hormone	Commercial	ROW
Exenatide USP	Antidiabetic GLP1 receptor agonist	Commercial	ROW
Terlipressin Acetate EP	Antidiuretic hormone	Commercial	ROW
Vasopressin IP	Osteoprosis treatment	Commercial	ROW
Vasopressin USP	Osteoprosis treatment	Commercial	ROW
Teriparatide EP	Chronic weight management	Commercial	ROW
Teriparatide IP	Chronic weight management	Commercial	ROW
Teriparatide USP	Chronic weight management	Commercial	ROW
Buserelin BP	Anti-cancer	Commercial	ROW
Buserelin IP	Anti-cancer	Commercial	ROW
Bivalirudin	Anti-coagulant/Anti-thrombin	Commercial	ROW
Glatiramer Acetate	Immunomodulators	Commercial	ROW
Atosiban Acetate IP	Halt premature labor	Commercial	ROW

* Developed for US/Eu/ROW markets.

List of Peptide API

Molecules*	Therapeutic class	Stage	Commercial For
Sincalide	Secretagogues	Under Development	—
Liraglutide	Type II anti-Diabetic	Under Development	—
Carfilzomib	Anticancer	Dev. completed, Tech transferred	—
Linaclotide	Constipation treatment	Under Development	—

Plecanatide	Type II anti-Diabetic	Under Development	—
Abaloparatide	Treatment of osteoporosis	Commercial	ROW
Semaglutide	Treatment of Acromegaly	Under Development	—
Lanreotide Acetate	Constipation treatment	Under Development	—
Setmelanotide	Type II anti-Diabetic	Under Development	—
Tirzepatide	Vasopressin agonist	Commercial	ROW
Carbetocin	Uterotonic Agent	Commercial	ROW
Felypressin	Anti-diuretic Hormone	Under Development	—
Difelikefalin	analgesic	Under development	—
Bremelanotide	Melanocortin receptor agonists	Under development	—
Cagrilintide	Anti-obesity	Under development	—
Pasireotide	Somatostatin agonists, treatment of Cushing's disease	Under development	—
Trofinetide	Treat rett syndrom	Under development	—
Dulaglutide	Antidiabetic		
List of Semi-synthetic API			
Molecules*	Therapeutic class	Stage	Commercial For
Everolimus	Immunosuppressant	Pilot Scale completed	—

Dalbavancin	Antibacterial	Under Development	—
Obeticholic acid	Treatment of Primary Biliary Cholangitis	Pilot Scale completed	—
Midostaurin	Anticancer	Pilot Scale completed	—
Sarecycline	Antibiotic	Pilot Scale completed	—
Omadacycline	Antibiotic	Under Development	—
Voclosporine	Treatment of Lupus nephritis	Under Development	—
Ibrexafungerp Citrate	Anti Fungal	Under Development	—
Rezafungin Acetate	Anti Fungal	Under Development	—
* Developed for US/Eu/ROW markets.			
List of Oligonucleotides			
Molecules*	Therapeutic class	Stage	Commercial For
Nusinersen	Treatment of spinal muscular atrophy (SMA)	Under Planning	—
Patisiran	Treatment of polyneuropathy of hereditary transthyretinmediated amyloidosis in adults	Under Planning	—
Inclisiran	Antilipemic agent	Under development	
* For Development for US/Eu/ROW markets.			

List Of Recombinant Peptides

Molecules*	Therapeutic class	Stage	Commercial For
Semaglutide	Type II anti-Diabetic	Under Planning	—
Liraglutide	Type II anti-Diabetic	Under Planning	—

* For Development for US/Eu/ROW markets.

List of Synthetic API

Molecules*	Therapeutic class	Stage	Commercial For
Mebendazole, Form A	Anthelmintic	Commercial	ROW
Bedaquiline	Antituberculosis	Commercial	ROW
Sugammadex Sodium	Reversal of neuromuscular blocker	Patent Out-licensed	—
Isavuconazonium sulfate	Antifungal	Pilot Scale completed	—
Remdesivir	Antiviral	Pilot Scale completed	—
Nitisinone	Hydroxy-phenylpyruvate dioxygenase inhibitor	Pilot Scale completed	—
Saroglitazar Mg	Antidiabetic	Under Development	—
Deutetrabenazine	Vesicular monoamine transporter 2 (VMAT2) inhibitors	Under Development	—
Rufinamide	Anti-epileptic	Under Development	—
Selexipag	Prostacyclin receptor agonist	Under Development	—
Vismodegib	Hedgehog pathway inhibitor	Under Development	—

Baricitinib	Janus kinase (JAK) inhibitor	Under Development	—
Apremilast	Anti-psoriatic	Under Development	—
Brexanolone	Antidepressant	Under Development	—
Brivaracetam	Anti-epileptic	Under Development	—
Molnupiravir	Anti-viral	Under Development	—
Tetrabenazine	Vesicular monoamine transporter 2 (VMAT) inhibitor	Under Development	—
SNAC	Oral peptide absorption promoter	Under Development	—
Empagliflozin	Antidiabetic	Under Development	—
Dapagliflozin	Antidiabetic	Under Development	—
Canagliflozin	Antidiabetic	Under Development	—
Pirfenidone	Idiopathic pulmonary fibrosis	Under Development	—
Midodrine	Vasoconstrictor, anti-hypotensive	Under Development	—
Crisaborole	Anti-dermatitis	Under Development	—
Fulvestrant	Antineoplastic agent	Under Development	—
Nintedanib Mesylate	Anti-fibrosis	Under Development	—

Nitisinone	Hydroxy-phenylpyruvate dioxygenase inhibitor	Under Development	—
Saroglitazar Mg	Antidiabetic	Under Development	—
Erdafitinib	Anticancer	Under Development	—
Isosulfan Blue	Adjunct to lymphography	Under Development	—
Vonoprazan	Potassium-competitive acid blocker (PCAB)	Under Development	—
Pretomanid	Antimycobacterial	Under Development	—
Delamanid	Antimycobacterial	Under Development	—
Venetoclax	Anticancer	Under Development	—
Ribociclib	Kinase inhibitor	Under Development	—
Tedizolid	Oxazolidinone antibiotics	Under Development	—
Alogliptin	Oral anti-diabetic drug	Under Development	—
Bempedoic acid	Hypercholesterolemia treatment	Under Development	—
Tavaborole	Antifungal agent	Under Development	—
Vortioxetine	Antidepressant	Under Development	—
Lifitegrast	Dry eye treatment	Dev to be initiated	—

Binimetinib	Anticancer	Dev to be initiated	—
Lumacaftor	Treatment of cystic fibrosis	Under Development	—
Sotorasib	Anti-cancer	Under Development	—
* Developed for US/Eu/ROW markets.			

List of Formulations under Development

Liquid Injectables.	<ul style="list-style-type: none"> • Carbetocin injection 100 micrograms/mL in glass vials.
	<ul style="list-style-type: none"> • Brexanolone injection, 100 mg brexanolone in 20 mL (5 mg/mL) aq. Solution.
	<ul style="list-style-type: none"> • Sugammadex injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) in a single-dose vial.
	<ul style="list-style-type: none"> • Ganirelix Acetate injection in 1 mL prefilled glass syringes containing 250 mcg/0.5 mL as aqueous solution.
Lyophilized Injections.	<ul style="list-style-type: none"> • Cetrorelix Acetate for injection: 0.25 mg cetrorelix/ vial.
	<ul style="list-style-type: none"> • Micafungin for injection, 50 mg micafungin (equivalent to 50.86 mg micafungin sodium) or 100 mg micafungin (equivalent to 101.73 mg

	micafungin sodium).
	• Anidulafungin for injection, 50mg & 100 mg/vial.
	• Degarelix for injection 120 mg of degarelix (equivalent to the median
	value of 126 mg degarelix acetate) and
	80mg (equivalent to the median
	value of 84 mg degarelix acetate).
Solid Orals tablets/ capsules.	• Sarecycline film coated tablets, 60 mg, 100 mg, and 150 mg.
	• Saroglitazar Calcium tablets 2mg and 4mg.
	• Everolimus tablet 0.25mg.
Complex Generics (Oral Peptides).	• Semaglutide Tablets 3 mg, 7 mg, 14 mg.
	• Linaclotide Hard Gelatin Capsule, 72 mcg, 145 mcg and 290 mcg.
	• Plecanatide Tablets 3mg.
Complex Novel Injectables.	• Triptorelin Acetate Microgranules injectable suspension 3.75mg per
	vial every 4week, 11.25 mg per vial every 12 weeks; 22.5 mg per vial
	for every 24 weeks.
	• Leuprolide Acetate for depot suspension (lyophilized microspheres),

	3.75 mg (1M), 7.5 mg (1M), 22.5 mg (3M), 30 mg (4M), and 45 mg
	(6M) per vial for injection.
	<ul style="list-style-type: none">• Octreotide Acetate lyophilized microspheres for injectable suspension,
	10 mg, 20 mg or 30 mg per vial strength.